糖尿病前期市场按治疗/管理、性别、年龄层、分销管道、体重类别、最终用户和地区划分

2025 年糖尿病前期市场规模估计为 88.1 亿美元，预计 2032 年将达到 151 亿美元，2025 年至 2032 年的复合年增长率为 8.1%。

全球糖尿病前期市场是更广泛的糖尿病管理生态系统中一个关键的细分市场，致力于解决第二型糖尿病发病前普遍存在的葡萄糖耐受不良和血糖值。糖尿病前期的特征是血糖值高于正常水平，但未达到糖尿病阈值，影响全球数百万人，是预防糖尿病发展的关键干预窗口。

这个市场包括专为糖尿病前期设计的诊断工具、治疗性介入、监测设备和生活方式管理解决方案。肥胖率上升、久坐不动的生活方式和人口老化导致糖尿病前期发病率上升，促使全球医疗保健系统优先考虑早期发现和干预策略。这个市场的重要性不仅限于眼前的医疗保健需求，还在于透过预防性照护方法实现长期成本节约。主要相关人员包括开发降血糖药物的製药公司、开发连续血糖监测系统的医疗设备製造商、提供筛检测试的筛检实验室以及提供生活方式干预计划的数位健康平台。糖尿病前期市场的发展反映了医疗保健产业向预防性护理的模式转移，强调早期疗育以减少糖尿病相关併发症和医疗保健支出，同时透过及时识别和管理血糖代谢异常来改善患者的预后。

市场动态

全球糖尿病前期市场正经历强劲成长，这得益于推动市场扩张和技术创新的若干相互关联的因素。关键驱动因素包括全球糖尿病前期盛行率的上升，估计全球有3.74亿成年人患有葡萄糖耐受不良，这带来了对诊断和治疗解决方案的巨大需求。此外，非侵入性血糖监测设备和数位健康平台的技术进步正在增强患者参与度和监测能力。然而，该市场也面临许多限制因素，包括新兴市场医疗基础设施有限、持续血糖监测系统高成本，以及许多医疗体系对糖尿病前期管理计画的报销不足。

此外，患者对生活方式改变和药物依从性的挑战仍然是市场渗透的持续障碍。儘管有这些限制，但透过开发利用基因检测和生物标记识别的个人化医疗方法，糖尿病前期的个人化介入正在涌现出巨大的机会。人工智慧和机器学习与糖尿病风险评估预测分析的整合正在开闢新的市场管道，而远距远端医疗能力和远端患者监护解决方案的扩展正在解决就医的地理障碍。此外，製药公司越来越注重开发针对糖尿病前期的新型疗法，加上强调预防性医疗保健的企业健康计划的扩展，正在为整个糖尿病前期管理领域的相关人员创造更多市场机会。

本次调查的主要特点

• 本报告对全球糖尿病前期市场进行了详细分析，并以 2024 年为基准年，给出了预测期（2025-2032 年）的市场规模和年复合成长率（CAGR%）。
• 它还强调了各个领域的潜在商机，并说明了针对该市场的引人注目的投资提案。
• 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。
• 它根据公司亮点、产品系列、关键亮点、财务表现和策略等参数概述了全球糖尿病前期市场的主要企业。
• 本报告的见解将使负责人和企业经营团队能够就未来的产品发布、新兴车型、市场扩张和行销策略做出明智的决策。
• 本研究报告针对该产业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
• 相关人员将透过用于分析全球糖尿病前期市场的各种策略矩阵更轻鬆地做出决策。

目录

第一章：调查目标和先决条件

• 调查目的
• 先决条件
• 简称

第二章 市场展望

• 报告描述
  • 市场定义和范围
• 执行摘要

第三章：市场动态、法规与趋势分析

• 市场动态
• 驱动程式
• 抑制因素
• 机会
• 影响分析
• 主要进展
• 监管情景
• 产品发布/核准
• PEST分析
• 波特分析
• 併购场景
• 产业趋势

4. 2020 年至 2032 年全球糖尿病前期市场（依治疗及管理）

• Metformin
• 数位健康和穿戴设备
• 血糖值监测设备（CGM、BGM）
• 草药补充剂
• 其他（益生菌、肠道环境改善产品等）

5. 2020-2032 年全球糖尿病前期市场（依性别）

• 男性
• 女士

6. 2020 年至 2032 年按年龄分類的全球糖尿病前期市场

• 成人
• 孩子们

7. 2020-2032 年全球糖尿病前期市场（依通路划分）

• 在线的
• 离线

8. 2020 年至 2032 年按体重类别分類的全球糖尿病前期市场

• 超重和肥胖人群（主要目标群）
• 体重正常但有代谢风险的个体（未确诊族群）

9. 2020 年至 2032 年全球糖尿病前期市场（依最终使用者划分）

• 医院
• 诊断实验室
• 居家照护环境
• 专科诊所
• 健康与健康中心

10. 2020 年至 2032 年全球糖尿病前期市场（按地区）

• 北美洲
  • 美国
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
• 欧洲
  • 德国
  • 英国
  • 西班牙
  • 法国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • ASEAN
  • 其他亚太地区
• 中东
  • 海湾合作委员会国家
  • 以色列
  • 其他中东地区
• 非洲
  • 南非
  • 北非
  • 中部非洲

第十一章竞争格局

• Bristol-Myers Squibb
• Mylan Pharmaceuticals
• Teva Pharmaceuticals
• Sun Pharmaceutical Industries
• Sandoz（Novartis）
• Glenmark
• Dexcom
• Abbott Laboratories
• Medtronic
• Ascensia Diabetes Care
• Senseonics
• Herbalife Nutrition
• Nestle Health Science
• Danone

第 12 章分析师建议

• 机会
• 分析师观点
• Coherent Opportunity Map

第十三章参考文献与调查方法

• 参考
• 调查方法
• 关于出版商

Prediabetes Market is estimated to be valued at USD 8.81 Bn in 2025 and is expected to reach USD 15.10 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.1% from 2025 to 2032.

The global prediabetes market represents a critical segment within the broader diabetes management ecosystem, addressing the growing prevalence of impaired glucose tolerance and elevated blood sugar levels that precede type 2 diabetes onset. Prediabetes, characterized by blood glucose levels higher than normal but not yet reaching diabetic thresholds, affects millions worldwide and serves as a crucial intervention window for preventing progression to full-blown diabetes.

The market encompasses diagnostic tools, therapeutic interventions, monitoring devices, and lifestyle management solutions specifically designed for prediabetic populations. With rising obesity rates, sedentary lifestyles, and aging demographics contributing to increased prediabetes prevalence, healthcare systems globally are prioritizing early detection and intervention strategies. The market's significance extends beyond immediate healthcare needs, encompassing long-term cost reduction through preventive care approaches. Key stakeholders include pharmaceutical companies developing glucose-lowering medications, medical device manufacturers creating continuous glucose monitoring systems, diagnostic laboratories offering screening tests, and digital health platforms providing lifestyle intervention programs. The prediabetes market's evolution reflects the healthcare industry's paradigm shift toward preventive medicine, emphasizing early intervention to reduce diabetes-related complications and healthcare expenditures while improving patient outcomes through timely identification and management of glucose metabolism disorders.

Market Dynamics

The global prediabetes market experiences robust growth, driven by several interconnected factors that collectively propel market expansion and innovation. Primary drivers include the escalating global prevalence of prediabetes, with an estimated 374 million adults worldwide living with impaired glucose tolerance, creating substantial demand for diagnostic and therapeutic solutions. Increasing healthcare awareness campaigns and government initiatives promoting early diabetes screening contribute significantly to market growth, as do technological advancements in non-invasive glucose monitoring devices and digital health platforms that enhance patient engagement and monitoring capabilities. However, the market faces notable restraints including limited healthcare infrastructure in developing regions, high costs associated with continuous glucose monitoring systems, and insufficient reimbursement coverage for prediabetes management programs in many healthcare systems.

Additionally, patient compliance challenges with lifestyle modifications and medication adherence present ongoing obstacles to market penetration. Despite these constraints, substantial opportunities emerge through the development of personalized medicine approaches utilizing genetic testing and biomarker identification for tailored prediabetes interventions. The integration of artificial intelligence and machine learning in predictive analytics for diabetes risk assessment opens new market avenues, while expanding telemedicine capabilities and remote patient monitoring solutions address geographical barriers to care access. Furthermore, pharmaceutical companies' increasing focus on developing novel therapeutic agents specifically targeting prediabetic populations, combined with growing corporate wellness programs emphasizing preventive healthcare, creates additional market opportunities for stakeholders across the prediabetes management spectrum.

Key Features of the Study

• This report provides an in-depth analysis of the global prediabetes market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global prediabetes market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Bristol-Myers Squibb, Mylan Pharmaceuticals, Teva Pharmaceuticals, Sun Pharmaceutical Industries, Sandoz (Novartis), Glenmark, Dexcom, Abbott Laboratories, Medtronic, Ascensia Diabetes Care, Senseonics, Herbalife Nutrition, Nestle Health Science, and Danone
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global prediabetes market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global prediabetes market

Market Segmentation

• Treatment & Management Insights (Revenue, USD Bn, 2020 - 2032)
  • Metformin
  • Digital Health and Wearables
  • Glucose Monitoring Devices (CGM, BGM)
  • Herbal Supplements
  • Others (Probiotics and Gut Health Products, etc.)
• Gender Insights (Revenue, USD Bn, 2020 - 2032)
  • Male
  • Female
• Age Group Insights (Revenue, USD Bn, 2020 - 2032)
  • Adult
  • Pediatric
• Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
  • Online
  • Offline
  • Specialty Pharmacies and Drugstores
  • Supermarkets or Hypermarkets
• Weight Category Insights (Revenue, USD Bn, 2020 - 2032)
  • Overweight and Obese Individuals (Primary Target)
  • Normal Weight with Metabolic Risk (Underdiagnosed Segment)
• End User Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospitals
  • Diagnostic Laboratories
  • Home Care Settings
  • Specialty Clinics
  • Health and Wellness Centers
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Bristol-Myers Squibb
  • Mylan Pharmaceuticals
  • Teva Pharmaceuticals
  • Sun Pharmaceutical Industries
  • Sandoz (Novartis)
  • Glenmark
  • Dexcom
  • Abbott Laboratories
  • Medtronic
  • Ascensia Diabetes Care
  • Senseonics
  • Herbalife Nutrition
  • Nestle Health Science
  • Danone

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Prediabetes Market, By Treatment & Management
  • Global Prediabetes Market, By Gender
  • Global Prediabetes Market, By Age Group
  • Global Prediabetes Market, By Distribution Channel
  • Global Prediabetes Market, By Weight Category
  • Global Prediabetes Market, By End User
  • Global Prediabetes Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Driver
• Restraint
• Opportunity
• Impact Analysis
• Key Developments
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Industry Trends

4. Global Prediabetes Market, By Treatment & Management, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Metformin
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Digital Health and Wearables
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Glucose Monitoring Devices (CGM, BGM)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Herbal Supplements
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others (Probiotics and Gut Health Products, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Prediabetes Market, By Gender, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Male
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Female
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Prediabetes Market, By Age Group, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Adult
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Pediatric
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Prediabetes Market, By Distribution Channel, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Online
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Offline
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Specialty Pharmacies and Drugstores
    • Supermarkets or Hypermarkets

8. Global Prediabetes Market, By Weight Category, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Overweight and Obese Individuals (Primary Target)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Normal Weight with Metabolic Risk (Underdiagnosed Segment)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Prediabetes Market, By End User, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospitals
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Diagnostic Laboratories
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Home Care Settings
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Specialty Clinics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Health and Wellness Centers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

10. Global Prediabetes Market, By Region, 2020 - 2032, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Treatment & Management, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Weight Category, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Treatment & Management, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Weight Category, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Treatment & Management, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Weight Category, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Treatment & Management, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Weight Category, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Treatment & Management, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Weight Category, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Treatment & Management, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Weight Category, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

11. Competitive Landscape

• Bristol-Myers Squibb
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Mylan Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Teva Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sun Pharmaceutical Industries
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sandoz (Novartis)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Glenmark
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Dexcom
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Abbott Laboratories
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Medtronic
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Ascensia Diabetes Care
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Senseonics
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Herbalife Nutrition
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Nestle Health Science
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Danone
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

12. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

13. References and Research Methodology

• References
• Research Methodology
• About us